1. Economic evaluation of hysteroscopic endometrial ablation versus vaginal hysterectomy for menorrhagia;Vilos;Obstet Gynecol,1996
2. US Food and Drug Administration, Center for Devices and Radiological Health. P010013 NovaSure™ impedence-controlled endometrial ablation system, approval letter, September 28, 2001. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/p100034a.pdf. Accessed September 3, 2016.
3. US Food and Drug Administration. Summary of safety and effectiveness: P010013 NovaSure™ impedance-controlled endometrial ablation system. http://www.accessdata.fda.gov/cdrh_docs/pdf/P010013B.pdf. Accessed September 3, 2016.
4. Ten-year literature review of global endometrial ablation with the NovaSure® device;Gimpelson;Int J Women's Health,2014
5. NovaSure® impedance-controlled system for endometrial ablation: three-year follow-up on 107 patients;Gallinat;Am J Obstet Gynecol,2004